Results 121 to 130 of about 14,835 (171)
Linking FHIR-Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System. [PDF]
Learn Health SystLeGrand J +5 more
europepmc +1 more source
Evidence for Potentiation of M-Type Potassium Current by Flavonoid Corylin (3-(2,2-Dimethylchromen-6-yl)-7-hydroxychromen-4-one). [PDF]
Pharmaceuticals (Basel)Wu SN, Liutkevičienė R, Lin SC.
europepmc +1 more source
Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension. [PDF]
Hepatobiliary Surg NutrSemmler G, Jachs M, Mandorfer M.
europepmc +1 more source
Sacubitril/valsartan facilitates recovery of cardiac function in a patient with peripartum cardiomyopathy: a case report. [PDF]
Eur Heart J Case RepSaijo Y +4 more
europepmc +1 more source
Modulation of inflammatory and adrenergic pathways in hypertension: effects of β-blockers on cytokine release in Jurkat T cells. [PDF]
Acta Biochim PolKajaia N +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2013
Carvedilol ((2RS)-1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol), a β1-, β2-, and α1-adrenoreceptor blocker drug with antioxidant and antiproliferative effects, is indicated for treatment of hypertension, stable angina pectoris, and congestive heart failure.
Kevin, Beattie +2 more
openaire +3 more sources
Carvedilol ((2RS)-1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol), a β1-, β2-, and α1-adrenoreceptor blocker drug with antioxidant and antiproliferative effects, is indicated for treatment of hypertension, stable angina pectoris, and congestive heart failure.
Kevin, Beattie +2 more
openaire +3 more sources
The pharmacology of carvedilol
European Journal of Clinical Pharmacology, 1990Carvedilol is a potent antihypertensive agent with a dual mechanism of action. At relatively low concentrations it is a competitive beta-adrenoceptor antagonist and a vasodilator, whereas at higher concentrations it is also a calcium channel antagonist.
R R, Ruffolo +4 more
openaire +2 more sources